Inmune Bio, Inc. (INMB) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does Inmune Bio, Inc. Do?
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. Inmune Bio, Inc. (INMB) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Raymond J. Tesi and employs approximately 10 people. With a market capitalization of $33M, INMB is one of the notable companies in the Healthcare sector.
Inmune Bio, Inc. (INMB) Stock Rating — Avoid (April 2026)
As of April 2026, Inmune Bio, Inc. receives a Avoid rating with a composite score of 18.8/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.INMB ranks #4,306 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Inmune Bio, Inc. ranks #786 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
INMB Stock Price and 52-Week Range
Inmune Bio, Inc. (INMB) currently trades at $1.18. The stock lost $0.10 (7.8%) in the most recent trading session. The 52-week high for INMB is $11.64, which means the stock is currently trading -89.9% from its annual peak. The 52-week low is $1.21, putting the stock -2.0% above its annual trough. Recent trading volume was 448K shares, suggesting relatively thin trading activity.
Is INMB Overvalued or Undervalued? — Valuation Analysis
Inmune Bio, Inc. (INMB) carries a value factor score of 9/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.44x, versus the sector average of 2.75x. The price-to-sales ratio is 675.27x, compared to 1.66x for the average Healthcare stock.
At current multiples, Inmune Bio, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.
Inmune Bio, Inc. Profitability — ROE, Margins, and Quality Score
Inmune Bio, Inc. (INMB) earns a quality factor score of 19/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -224.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -163.1% versus the sector average of -33.1%.
The operating margin is -19810.0% (sector: -66.1%). Net profit margin stands at -19478.0%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
INMB Debt, Balance Sheet, and Financial Health
Inmune Bio, Inc. has a debt-to-equity ratio of 38.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 3.55x, indicating strong short-term liquidity. Total debt on the balance sheet is $623,000. Cash and equivalents stand at $28M.
INMB has a beta of 1.72, meaning it is more volatile than the broader market — a $10,000 investment in INMB would be expected to move 72.5% more than the S&P 500 on any given day. The stability factor score for Inmune Bio, Inc. is 18/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.
Inmune Bio, Inc. Revenue and Earnings History — Quarterly Trend
In TTM 2026, Inmune Bio, Inc. reported revenue of $50,000 and earnings per share (EPS) of $-1.86. Net income for the quarter was $-53M. Operating income came in at $-54M.
In FY 2025, Inmune Bio, Inc. reported revenue of $50,000 and earnings per share (EPS) of $-1.86. Net income for the quarter was $-46M. Revenue grew 257.1% year-over-year compared to FY 2024. Operating income came in at $-47M.
In Q3 2025, Inmune Bio, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.24. Net income for the quarter was $-6M. Operating income came in at $-7M.
In Q2 2025, Inmune Bio, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.05. Net income for the quarter was $-24M. Operating income came in at $-25M.
Over the past 8 quarters, Inmune Bio, Inc. has demonstrated a growth trajectory, with revenue expanding from $0 to $50,000. Investors analyzing INMB stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
INMB Dividend Yield and Income Analysis
Inmune Bio, Inc. (INMB) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
INMB Momentum and Technical Analysis Profile
Inmune Bio, Inc. (INMB) has a momentum factor score of 12/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 44/100 reflects moderate short selling activity.
INMB vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, Inmune Bio, Inc. (INMB) ranks #786 out of 838 stocks based on the Blank Capital composite score. This places INMB in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing INMB against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full INMB vs S&P 500 (SPY) comparison to assess how Inmune Bio, Inc. stacks up against the broader market across all factor dimensions.
INMB Next Earnings Date
No upcoming earnings date has been announced for Inmune Bio, Inc. (INMB) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy INMB? — Investment Thesis Summary
The quantitative profile for Inmune Bio, Inc. suggests caution. The quality score of 19/100 flags below-average profitability. The value score of 9/100 indicates premium valuation. Momentum is weak at 12/100, a headwind for near-term performance. High volatility (stability score 18/100) increases portfolio risk.
In summary, Inmune Bio, Inc. (INMB) earns a Avoid rating with a composite score of 18.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on INMB stock.
Related Resources for INMB Investors
Explore more research and tools: INMB vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare INMB head-to-head with peers: INMB vs AZN, INMB vs SLGL, INMB vs VMD.